Please ensure Javascript is enabled for purposes of website accessibility

MediPharm Sinks by Over 14% on Q1 Results

By Eric Volkman – Jun 18, 2020 at 6:59PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A steep fall in demand and the economic ravages of the coronavirus badly affected the company's business.

MediPharm Labs (MEDIF 3.18%) was not a bright star in the marijuana industry on Thursday. The cannabis-extraction specialist's stock took a nasty hit following the release of Q1 of fiscal 2020 results that morning.

MediPharm recorded some dramatic declines during the period. Revenue fell by nearly 50% on a year-over-year basis to 11.1 million Canadian dollars ($8.2 million). This represented a deeper sequential fall, as the Q4 2019 result was CA$32.4 million ($23.9 million).

Two hands holding cannabis extract in a jar.

Image source: Getty Images.

The situation wasn't any happier on the bottom line. MediPharm posted a pre-tax net loss of just over CA$22 million ($16.2 million). That was far deeper than the year-ago shortfall of roughly CA$325,000 ($239,830) and the preceding quarter's CA$2.4 million ($1.8 million) loss.

Few analysts follow the stock, so it was not immediately clear what the general expectations were for the quarter.

MediPharm attributed its declines to a reduction in both the selling prices and volume of its bulk extracts. This, it said in the earnings release, was due to "continued muted demand in the Canadian bulk wholesale market." Although the company has been notching successes in foreign markets such as Australia lately, it's still heavily anchored in its native country.

The SARS-CoV-2 coronavirus also had a deleterious effect on the company's business. MediPharm said that delayed dispensary openings led to lower orders for its goods. Finally, a CA$12.8 million ($9.4 million) inventory writedown hurt the bottom line considerably.

The company did, however, sound an optimistic note on its prospects. "The Canadian market is still developing and MediPharm Labs will be the beneficiary as retail channels and available products expand," it wrote.

Investors seem to feel differently, though. MediPharm's shares cratered by almost 14.3% on Thursday, a far worse performance than that of the broader stock market.

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

MediPharm Labs Corp. Stock Quote
MediPharm Labs Corp.
$0.06 (3.18%) $0.00

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/25/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.